Madopar HBS and the decompensated phase of Parkinson disease

T. Caraceni; N. Nordera; E. Lamperti; A. Lorizio

doi:10.1007/BF02334945

Madopar HBS and the decompensated phase of Parkinson disease

T. Caraceni, N. Nordera, E. Lamperti, A. Lorizio

Fondazione IRCCS Istituto Neurologico "C. Besta"

Research output: Contribution to journal › Article › peer-review

Abstract

The most important current problem in the treatment of Parkinson disease in the so-called L-dopa long-term-treatment syndrome. We present here the results of our experience with Madopar HBS in the treatment of two groups of patients suffering from L-dopa long-term treatment syndrome. In the first study we replaced the standard Madopar with Madopar HBS. In the second study, after identifying the most disabling "off" periods, we added Madopar HBS to the previous treatment in such a way as to control these "off" phases. Our study suggests that Madopar HBS is useful in reducing typical fluctuation phenomena in the majority of patients.

Original language	English
Pages (from-to)	407-414
Number of pages	8
Journal	Italian Journal of Neurological Sciences
Volume	10
Issue number	4
DOIs	https://doi.org/10.1007/BF02334945
Publication status	Published - Aug 1989

Keywords

decompensated phase
Madopar HBS
Parkinson disease

ASJC Scopus subject areas

Neuroscience(all)
Clinical Neurology

Access to Document

10.1007/BF02334945

Fingerprint Dive into the research topics of 'Madopar HBS and the decompensated phase of Parkinson disease'. Together they form a unique fingerprint.

Cite this

@article{ddec2ec3f4c444c49c584678ab758708,

title = "Madopar HBS and the decompensated phase of Parkinson disease",

abstract = "The most important current problem in the treatment of Parkinson disease in the so-called L-dopa long-term-treatment syndrome. We present here the results of our experience with Madopar HBS in the treatment of two groups of patients suffering from L-dopa long-term treatment syndrome. In the first study we replaced the standard Madopar with Madopar HBS. In the second study, after identifying the most disabling {"}off{"} periods, we added Madopar HBS to the previous treatment in such a way as to control these {"}off{"} phases. Our study suggests that Madopar HBS is useful in reducing typical fluctuation phenomena in the majority of patients.",

keywords = "decompensated phase, Madopar HBS, Parkinson disease",

author = "T. Caraceni and N. Nordera and E. Lamperti and A. Lorizio",

year = "1989",

month = aug,

doi = "10.1007/BF02334945",

language = "English",

volume = "10",

pages = "407--414",

journal = "Italian Journal of Neurological Sciences",

issn = "0392-0461",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Madopar HBS and the decompensated phase of Parkinson disease

AU - Caraceni, T.

AU - Nordera, N.

AU - Lamperti, E.

AU - Lorizio, A.

PY - 1989/8

Y1 - 1989/8

N2 - The most important current problem in the treatment of Parkinson disease in the so-called L-dopa long-term-treatment syndrome. We present here the results of our experience with Madopar HBS in the treatment of two groups of patients suffering from L-dopa long-term treatment syndrome. In the first study we replaced the standard Madopar with Madopar HBS. In the second study, after identifying the most disabling "off" periods, we added Madopar HBS to the previous treatment in such a way as to control these "off" phases. Our study suggests that Madopar HBS is useful in reducing typical fluctuation phenomena in the majority of patients.

AB - The most important current problem in the treatment of Parkinson disease in the so-called L-dopa long-term-treatment syndrome. We present here the results of our experience with Madopar HBS in the treatment of two groups of patients suffering from L-dopa long-term treatment syndrome. In the first study we replaced the standard Madopar with Madopar HBS. In the second study, after identifying the most disabling "off" periods, we added Madopar HBS to the previous treatment in such a way as to control these "off" phases. Our study suggests that Madopar HBS is useful in reducing typical fluctuation phenomena in the majority of patients.

KW - decompensated phase

KW - Madopar HBS

KW - Parkinson disease

UR - http://www.scopus.com/inward/record.url?scp=0024447775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024447775&partnerID=8YFLogxK

U2 - 10.1007/BF02334945

DO - 10.1007/BF02334945

M3 - Article

C2 - 2793413

AN - SCOPUS:0024447775

VL - 10

SP - 407

EP - 414

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

SN - 0392-0461

IS - 4

ER -

Madopar HBS and the decompensated phase of Parkinson disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this